Table 1. Selection criteria for CRS-HIPEC in PM of gastric origin.
| Complete cytoreduction possible (CC0) |
| Low tumor burden (PCI <6) |
| Locoregional PM (P1) |
| No small bowel involvement |
| Synchronous PM |
| Well-moderately differentiated tumors |
| No signet ring cell type |
| Good performance status (ECOG 0) |
| Prior response to systemic chemotherapy |
CRS-HIPEC, cytoreductive surgery-hyperthermic intraperitoneal chemotherapy; PM, peritoneal metastases; PCI, Peritoneal Cancer Index.